


“ This award has been instrumental in establishing my independent research career. It allowed me to translate my basic research findings from animal models to humans and compete for future funding opportunities. ”

Adam Snook, Ph.D.
Thomas Jefferson University
Research Starter Grant in
Translational Medicine and
Therapeutics



2016 Awards in TRANSLATIONAL MEDICINE AND THERAPEUTICS

PhRMA
FOUNDATION

Pharmaceutical Research and
Manufacturers of America Foundation



Post Doctoral Fellowships
Research Starter Grants

Application Deadline: February 1, 2016

Award Details at www.phrmafoundation.org



Left to right:
Stefanie Sowinski, Ph.D.
 The J. David Gladstone Institutes
Michelle E. Kimple, Ph.D.
 University of Wisconsin-Madison
Sihem Ait Oudhia, Ph.D., PharmD
 SUNY, University at Buffalo

2016 Awards in TRANSLATIONAL MEDICINE AND THERAPEUTICS

The PhRMA Foundation funds scientists at critical points in their research careers to support and reward innovation in disciplines essential to the development of safe and effective medicines. The PhRMA Foundation offers competitive pre and post doctoral fellowships, sabbatical fellowships, and research starter grants to advance science in Adherence Improvement, Clinical Pharmacology, Comparative Effectiveness Research, Health Outcomes, Informatics, Pharmaceutics, Pharmacology/Toxicology, and Translational Medicine and Therapeutics.

Over the past 50 years, the PhRMA Foundation has helped thousands of scientists advance their careers and has inspired new generations to enter biopharmaceutical research. The early-career support provided by the PhRMA Foundation has been a catalyst for our scientists to become leaders in their organizations and fields. Our programs help build a larger pool of highly-trained researchers to meet the growing needs of academic institutions, the government and the research-intensive pharmaceutical industry.

PhRMA Foundation award recipients will continue to play an instrumental role in substantial achievements in medicine for the benefit of public health and ultimately the patient.

Area of Interest

Translational Medicine and Therapeutics

The goal of the PhRMA Foundation’s Translational Medicine and Therapeutics Program is to promote the development and use of experimental and computational methods in an integrative approach towards clinical needs in diagnosis, treatment and prevention. This can involve enhanced understanding of human biological and disease processes but requires a strong translational component. This program will support the concepts of Translational Medicine and Therapeutics as defined by the Foundation:

“Translational medicine and therapeutics is a discipline focused on bridging experimental and computational technologies and discoveries in the research laboratory to their application in clinical practice. Examples of research components include activities in the areas of molecular and cellular biology, pathophysiology, systems biology, bioinformatics, modeling and simulation, and other quantitative sciences to connect basic biological concepts and entities to directly address unmet medical needs. The goals are to efficiently advance the product of basic research to patients and to use clinical observation as the basis for hypothesis generation to further basic research.”

Translational medicine and therapeutics awards will advance training and support career development of scientists engaged in research that significantly integrates cutting-edge technologies with advanced biological, chemical, and pharmacological sciences and engineering methodologies in such areas as (but not restricted to):

Genetics (Molecular, Pharmaco-, Population, Medical)
 Genomics (Functional, Structural, Toxico-, Pharmaco-,Comparative)

Systems (Biology and Pharmacology)
 Pathways and networks
 Integrative biology
 Modeling and simulation
 Target Identification and Validation

Biomarker Discovery and Validation
 Vaccine Development
 Molecular Epidemiology
 Imaging
 Disease Modeling

continued on page 3



Left to right:
Katherine Theken, Ph.D., PharmD
University of Pennsylvania
Jun T. Wang, Ph.D.
University of California, Davis
Timothy Hohman, Ph.D.
Vanderbilt University Medical Center
Tarsheen Sethi, M.D., MBBS
University of Louisville

2016 Awards in TRANSLATIONAL MEDICINE AND THERAPEUTICS

Program Priorities

1. Emphasis will be placed on the development of new experimental and computational approaches and technologies that facilitate the translation of research data into an elucidation and understanding of human biological and disease processes to directly support clinical needs.
2. Preference will be given to those applicants whose research combines novel experimental and computational methods together with clinical research and application.
3. For applications to be considered, proposals must contain evidence of collaboration across the non-clinical:clinical interface and not solely apply experimental and computational methodologies to data analysis without clinical validation.
4. The use of non-human model systems must be described in terms of its relationship to human biology and disease and the results of such studies will require clinical testing in support of the model.

Foundation-supported research, including this program, encourages open-source development of algorithms and methodologies whenever possible and supports open data-sharing whenever appropriate, to further the goals of this program.

General Information

Eligibility Criteria

All applicants must be U.S. citizens or permanent residents. Before an individual is eligible to apply for a PhRMA Foundation award, an applicant must have a firm commitment from a university in the U.S. **Applications must be submitted by an accredited U.S. school.** Necessary documentation is described under the specific awards on the website.

Applications

All application components are listed on the website. www.phrmafoundation.org.

Online applications and required hardcopy materials must be completed and submitted by **February 1, 2016**. Applications will not be accepted after the deadline date.

Visit our website for detailed information regarding: use and care of laboratory animals; ethical considerations; required reporting; termination; and other relevant information.

All applicants will be notified no later than **April 15, 2016**.